Clinical and laboratory parameters of 3 generations of family members carrying C326S ferroportin mutation
Patient . | IA . | IIA . | IIB . | IIC . | IIIA . | IIIB . | IIIC . |
---|---|---|---|---|---|---|---|
Age at diagnosis/sex | 35/M | 16/F | 16/M | 16/M | 8/F | 10/F | 10/F |
Transferrin sat, initial | 97%* | 86%* | 94%* | 89%* | 84%* | 97%* | |
Transferrin sat, current | 79%* | 89%* | 70%* | 89%* | 93%* | 91%* | 51%* |
S-ferritin current, ng/mL | 69 | 99 | 81 | 394* | 114 | 21 | 11† |
S-hepcidin, ng/mL | 278* | 198 | 297* | 459* | 453* | 396* | 13† |
U-hepcidin, ng/mg creat | 1308 | 2743* | 2270* | 3183* | 3463* | 3036* | 72 |
Liver biopsy | Cirrhosis | ↑ hepatocyte iron | ↑ hepatocyte iron | ||||
Clinical | Arthritis, hip replacement | mild arthritis | mild arthritis | mild LFT changes |
Patient . | IA . | IIA . | IIB . | IIC . | IIIA . | IIIB . | IIIC . |
---|---|---|---|---|---|---|---|
Age at diagnosis/sex | 35/M | 16/F | 16/M | 16/M | 8/F | 10/F | 10/F |
Transferrin sat, initial | 97%* | 86%* | 94%* | 89%* | 84%* | 97%* | |
Transferrin sat, current | 79%* | 89%* | 70%* | 89%* | 93%* | 91%* | 51%* |
S-ferritin current, ng/mL | 69 | 99 | 81 | 394* | 114 | 21 | 11† |
S-hepcidin, ng/mL | 278* | 198 | 297* | 459* | 453* | 396* | 13† |
U-hepcidin, ng/mg creat | 1308 | 2743* | 2270* | 3183* | 3463* | 3036* | 72 |
Liver biopsy | Cirrhosis | ↑ hepatocyte iron | ↑ hepatocyte iron | ||||
Clinical | Arthritis, hip replacement | mild arthritis | mild arthritis | mild LFT changes |
Normal serum hepcidin median (5%-95% range) was 112 ng/mL (29-254 ng/mL) for men, and 65 ng/mL (17-286 ng/mL) for women. Normal urine hepcidin median (full range) was 502 ng/mg creatinine (71-1762 ng/mg creatinine). M indicates male; F, female; sat, saturation; and creat, creatinine.
Above-normal values.
Below-normal values.